QEEG Clinical Report

EEGLens





The QEEG report is provided by NPCindex Company, operating under the QEEGhome brand.

Personal Data:

Name: Matinnamdari

Gender: Male

Age: 2002-08-06 - 23.3

Handedness: Right

Clinical Data:

Initial diagnosis: Depression-Drug Abuse

Medication: -

Date of Recording: 2025-10-18

Source of Referral: Kamal Barzegar Ghazi

This case belongs to Kamal Barzegar Ghazi











EEG Quality

EC


Z-score Information



■ TMS Reponsibility



■ Pathological Assessment



■ EEG Neuromarker Values

Neuromarker	Region	Value	Assessment
AFP	Frontal	11.25	High
AFP	Occipital	11.25	High
Arousal Level	-	-	Normal

QEEGhome Clinical Report


Kamal Barzegar Ghazi





Denoising Information


Eye Close







Denoised EEG



Flat Channel



Total Recording Time Remaining: 199.33 sec

Number of Eye and Muscle Elements

Eye: 2 Muscle: 0

Low Artifact Percentage

High Artifact Percentage

Total Artifact Percentage


EEG Quality: perfect





Pathological Assessment

Main Diagnosis: Depression



Description

According to the guidelines, the initial diagnosis of depression could have comorbidities such as alcohol abuse, panic attacks, OCD, and anxiety. It also differentially diagnoses with anxiety, bipolar disorder, alcohol abuse, psychosis, and somatoform.

In the above graph, the **red area** shows the percentage of each comorbidity from your patient's EEG markers. Observe that each comorbidity marker is not unique and can be shared with other comorbidities.


Side circles in the above graph represent the differential diagnosis between depression and its misdiagnosis conditions based on your patient's EEG markers and trained artificial intelligence. The differential diagnosis probability is represented by **the bold blue bars** in the circles, and the probability of depression is represented by the gray bars.

Note: In case your patient has drug abuse, obtain the substance abuse pathologic page of QEEGhome by registering the diagnosis under the initial diagnoses section of the website.

References:

Sadock, B. J., Sadock, V. A., & Ruiz, P. (Eds.). (2025). Kaplan and Sadock's comprehensive textbook of psychiatry (11th ed., Vols. 1–2). Wolters Kluwer Sadock, B. J., Sadock, V. A., & Ruiz, P. (2022). Kaplan and Sadock's synopsis of


User Manual








Pathological Assessment for Substance Abuse



Depressants Stimulants

Functional Problems Source Detection

Eye Close



0

Depressants

Stimulants

Note


The Relapse graph displays the relapse index based on a combination of EEG neuromarkers. It is valid only if the patient has used each of the substances included in the chart; otherwise, the index is not applicable.


The Compatibility graph shows how closely the patient's EEG neuromarkers match typical EEG changes caused by specific substances. It helps identify the dominant substance effect in cases of multiple drug use. This index is also valid only if the patient has actually used the substances represented.





QEEG Based Predicting Medication Response





Explanation

These two tables can be considered the most important finding that can be extracted from QEEG. To prepare this list, the NPCIndex Article Review Team has studied, categorized, and extracted algorithms from many authoritative published articles on predict medication response and Pharmaco EEG studies. These articles are published between 1970 and 2021. The findings extracted from this set include 85 different factors in the raw band domains, spectrum, power, coherence, and loreta that have not been segregated to avoid complexity, and their results are shown in these diagrams. One can review details in NPCIndex.com .

Medication Recommendation

These two charts, calculate response probability to various medications, according only to QEEG indicators. Blue charts favor drug response and red charts favor drug resistance. The longer the bar, the more evidence there is in the articles. Only drugs listed in the articles are listed. These tables present the indicators reviewed in the QEEG studies and are not a substitute for physician selection.





rTMS Response Prediction

Network Performance


Accuracy: 92.10% Sensitivity: 89.13% Specificity: 97.47%

Participants Information







Features Information



Responsibility



Data Distribution




About Predicting rTMS Response

This index was obtained based on machine learning approaches and by examining the QEEG biomarkers of more than 470 cases treated with rTMS. The cases were diagnosed with depression (with and without comorbidity) and all were medication free. By examining more than 40 biomarkers capable of predicting response to rTMS treatment in previous studies and with data analysis, finally 10 biomarkers including bispectral and nonlinear features entered the machine learning process. The final chart can distinguish between RTMS responsive and resistant cases with 92.1% accuracy. This difference rate is much higher than the average response to treatment of 44%, in the selection of patients with clinical criteria, and is an important finding in the direction of personalized treatment for rTMS.






Vigilance



Vigilance Slope -0.50




EEG Neuromarker Values


Neuromarker	Region	Value	Assessment
APF	Frontal	11.25	High
APF	Occipital	11.25	High
Alpha Asymmetry	Frontal	00.12	Anxiety
Alpha Asymmetry	Occipital	00.04	Anxiety
Beta Asymmetry	Frontal	00.19	Anhedonia
Arousal Level		-	Normal
Vigilance Level		02.00	Low
Vigilance Mean		02.67	Normal
Vigilance Regulation		-0.50	Low
Vigilance 0 Stage (%)	-	00.00	Normal
Vigilance A1 Stage (%)		10.55	-





EEG Spectra











Z Score Summary Information

Eye Close




Theta/Beta Ratio







Absolute Power-Eye Close



Relative Power-Eye Close

